 |
|
|
|
October 1999 Cover
|
|
Roche Holding recently established a joint develo pment agreement with Trimeris to conduct human clinical trials and complete develo pment of two new
AIDS drugs, T-20 and T-1249. The companies will split research costs and earnings from the drugs in the United States and Canada, but Roche will hold global
marketing rights and handle develo pment costs in other countries. Previous studies of T-20, which is in Phase II human trials, showed it reduced the amount of HIV in a
patient's blood by as much as 99 percent in two weeks; T-1249 is only in the first stages of human testing.
Editor's Note: from the Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
